Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibikase TherapeuticsIKT +0.21%37 EV-to-EBIT is -4.43 as of Aug. 13, 2026. GuruFocus rates IKT with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 367 Biotechnology companies, Inhibikase Therapeutics ranks worse than 272479.29% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Inhibikase Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $159.76 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics EV-to-EBIT Related Terms
Inhibikase Therapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibikase Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's EV-to-EBIT falls into.
Inhibikase Therapeutics's current Enterprise Value is $290.82 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a EV-to-EBIT of -4.43 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry.
Is Inhibikase Therapeutics' EV-to-EBIT too high?
Inhibikase Therapeutics' current EV-to-EBIT is -4.43. Based on the distribution chart, Inhibikase Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' EV-to-EBIT compare to LXEO and XFOR?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #999999 out of 367 companies for EV-to-EBIT. This places Inhibikase Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.42, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current EV-to-EBIT is -4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current EV-to-EBIT of -4.43. The current EV-to-EBIT is -4.43. Inhibikase Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current EV-to-EBIT is -4.43 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
37GF Score
Get the complete analysis for IKT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
